Sanofi

Name

Sanofi

Legal name

Sanofi Sp. z o.o.

Website

https://sanofi.pl

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN), Public & Private Vaccine Provider Networks (Clinics/Pharmacies/Physicians) (HLAJAHAB)

Keywords

• Biopharmaceutical products
• Vaccine manufacturing
• Prescription pharmaceuticals
• Immunology research
• Clinical drug development

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Revenue from prescription pharmaceutical products across multiple therapeutic areas including immunology, oncology, and specialty care.
2. Vaccines: Seasonal influenza vaccines (VaxigripTetra) and other vaccines for public health protection, supplied annually based on vaccination rates and country demand.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Sanofi Polska develops, manufactures, and distributes pharmaceutical products and vaccines across five therapeutic areas, leveraging AI-integrated immunology science. Its most visible offerings include the VaxigripTetra seasonal influenza vaccine and Plavix antiplatelet medication, supplied via direct sales to pharmacies and hospitals through its Warsaw customer service, Rzeszów production site, and Błonie wholesale center. The company also supports the Campus Sanofi educational platform for physicians and runs patient support programs and rare disease awareness campaigns.

Product overview

Sanofi is an innovative biopharma company that operates across 5 therapeutic areas and has 93 substances in clinical development phase, with 26 clinical trials in phase 3. The company combines science with AI technology to develop and deliver pharmaceutical products and vaccines. Key products include VaxigripTetra® (influenza vaccine) and Plavix (prescription medication). Sanofi also operates Campus Sanofi, an educational platform for medical professionals. The company is positioned as a pioneer in immunology with over 50 years of experience, from the first polio vaccine to cutting-edge biological therapies.

Differentiator

Problem solved

Functional benefit

Brands

• VaxigripTetra: Influenza vaccine produced by Sanofi for seasonal flu protection.

Products and services

• VaxigripTetra Seasonal influenza vaccine produced by Sanofi for flu protection, supplied annually to Polish pharmacies, hospitals, and public health programs based on vaccination rates and country demand.
• Plavix Prescription antiplatelet medication available for ordering by pharmacies and hospitals through Sanofi's dedicated customer service line (222 800 980).
• Campus Sanofi Professional development and education platform for physicians and medical professionals to advance their knowledge and skills, operated at campus.sanofi/pl.
• Polish Atopic Disease Society Support Hotline (PTCA) Patient support hotline supported by Sanofi that provides patients with atopic diseases, their caregivers, and physicians access to information on reimbursed atopic dermatitis (AZS) therapies and free consultations with psychology, dietetics, and AZS therapy experts.

Quantifiable outcome

• 93 substances in clinical development pipeline
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

One partnership is on record.

• Fundacja Ronalda McDonalda (Ronald McDonald Foundation)minorStrategic or Co-development PartnerLocal partner of the WeVolunteer employee volunteering program. Sanofi volunteers supported the Ronald McDonald House and UCK WUM Pediatric Hospital, providing assistance to parents of neonatology and rare disease patients, as well as families of oncology and hematology patients.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GlaxoSmithKline (GSK) Poland: GSK's Polish subsidiary is a direct peer, competing head-to-head with Sanofi Polska in seasonal influenza vaccines and a broad pharmaceutical/vaccine portfolio supplied through the same pharmacy and hospital channels in Poland.
• Pfizer Poland: Pfizer's Polish subsidiary competes directly with Sanofi Polska across prescription pharmaceuticals, vaccines (including COVID and flu), and specialty/biological therapies, sharing similar hospital and pharmacy distribution channels in Poland.
• Roche Poland: Roche Poland is a direct peer in specialty pharmaceuticals and biologics, operating through similar hospital procurement channels and competing with Sanofi Polska in immunology and rare disease therapeutic areas in Poland.
• Novartis Poland: Novartis Poland competes with Sanofi Polska in prescription specialty pharmaceuticals, immunology, and rare disease treatments, accessing the same Polish hospital and reimbursement ecosystem.
• AstraZeneca Poland: AstraZeneca Poland is a direct peer in biopharmaceuticals and vaccines, with overlapping therapeutic area focus and shared hospital/pharmacy distribution channels in the Polish market.
• Merck Sharp & Dohme (MSD) Poland: MSD Poland competes with Sanofi Polska in vaccines and specialty pharmaceuticals, including HPV and oncology portfolios, using comparable medical information and hospital account management approaches in Poland.
• Johnson & Johnson Poland: J&J Poland's pharmaceutical division competes with Sanofi Polska in immunology, rare disease, and specialty care therapeutic areas through the same hospital, pharmacy, and physician channels.
• Seqirus (CSL): Seqirus is a direct peer in seasonal and pandemic influenza vaccines, directly competing with Sanofi's VaxigripTetra franchise for tender and procurement share across European markets including Poland.

Emerging players

• Moderna: Moderna is an emerging peer in mRNA-based vaccines, including influenza, that competes with Sanofi's flu vaccine franchise and is building European commercial presence that will increasingly overlap with Sanofi Polska's market.

Regional players

• Polfa Tarchomin: Polfa Tarchomin is a domestic Polish pharmaceutical manufacturer and competitor, overlapping with Sanofi Polska in prescription medicines distributed through Polish pharmacies and hospitals, though with a narrower product range.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sanofi
• Xx.com/sanofipolska

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi